Category: 890092-19-0

On July 14, 2011, Aissaoui, Hamed; Boss, Christoph; Corminboeuf, Olivier; Heidmann, Bibia; Siegrist, Romain published a patent.Quality Control of 4-(4-Acetylpiperazin-1-yl)benzaldehyde The title of the patent was Preparation of piperazines as antimalarial agents. And the patent contained the following:

The invention relates to piperazine derivatives of Formula I (wherein X is CH or N; R1 is -NO2, -NMe2, H, CN, etc.; and R2 is H, Me, CN, halo, etc.), and their use as active ingredients in the preparation of pharmaceutical compositions The invention also concerns related aspects including pharmaceutical compositions containing one or more of those compounds and their use as medicaments for the treatment or prevention of protozoal infections, such as especially malaria. Synthetic procedures for preparing I are exemplified. Example compound II, prepared by reacting the corresponding cinnamic acid derivative with amine intermediate III, was very effective in both in vivo and in vitro antimalarial assays. The experimental process involved the reaction of 4-(4-Acetylpiperazin-1-yl)benzaldehyde(cas: 890092-19-0).Quality Control of 4-(4-Acetylpiperazin-1-yl)benzaldehyde

The Article related to piperazine compound preparation antimalarial, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Quality Control of 4-(4-Acetylpiperazin-1-yl)benzaldehyde

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On April 18, 2019, Miracle, Gregory Scot; Valenti, Dominick Joseph; Dey, Sanjeev Kumar; Qin, Haihu; Freund, Wesley A. published a patent.Formula: C13H16N2O2 The title of the patent was Leuco colorants as bluing agents in laundry care compositions. And the patent contained the following:

A laundry care composition including (a) at least one laundry care ingredient and (b) at least one fluorescent moiety covalently bound to at least one second moiety selected from the group consisting of leuco moieties and chromophore moieties. A method of treating a textile includes the steps of (a) providing such a laundry care composition; (b) adding the laundry care composition to a liquid medium; (c) placing textile articles in the liquid medium; (d) optionally, rinsing the textile; and (e) drying the textile articles. The experimental process involved the reaction of 4-(4-Acetylpiperazin-1-yl)benzaldehyde(cas: 890092-19-0).Formula: C13H16N2O2

The Article related to leuco colorant bluing laundry care, Surface Active Agents and Detergents: Dry-Cleaning Solvents and Laundering Detergents (Cleaning Of Finished Garments) and other aspects.Formula: C13H16N2O2

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On April 18, 2019, Miracle, Gregory Scot; Valenti, Dominick Joseph; Dey, Sanjeev Kumar; Qin, Haihu; Freund, Wesley A. published a patent.Formula: C13H16N2O2 The title of the patent was Leuco colorants as bluing agents in laundry care compositions. And the patent contained the following:

A laundry care composition including (a) at least one laundry care ingredient and (b) at least one fluorescent moiety covalently bound to at least one second moiety selected from the group consisting of leuco moieties and chromophore moieties. A method of treating a textile includes the steps of (a) providing such a laundry care composition; (b) adding the laundry care composition to a liquid medium; (c) placing textile articles in the liquid medium; (d) optionally, rinsing the textile; and (e) drying the textile articles. The experimental process involved the reaction of 4-(4-Acetylpiperazin-1-yl)benzaldehyde(cas: 890092-19-0).Formula: C13H16N2O2

The Article related to leuco colorant bluing laundry care, Surface Active Agents and Detergents: Dry-Cleaning Solvents and Laundering Detergents (Cleaning Of Finished Garments) and other aspects.Formula: C13H16N2O2

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On February 15, 2020, Sirim, Mustafa Mert; Krishna, Vagolu Siva; Sriram, Dharmarajan; Unsal Tan, Oya published an article.Product Details of 890092-19-0 The title of the article was Novel benzimidazole-acrylonitrile hybrids and their derivatives: Design, synthesis and antimycobacterial activity. And the article contained the following:

The synthesis and evaluation of some benzimidazole-acrylonitrile hybrid derivatives I [R = Me, cyclohexyl, benzyl, etc.] was described for their in-vitro antimycobacterial activities against Mycobacterium tuberculosis H37Rv. Among the derivatives studied, I [R = p-tolyl] was found to be the most active compound with MIC of 0.78μg/mL against M. tuberculosis. This was a quite good activity compared with ethambutol (MIC = 1.56μg/mL). Moreover, I [R = p-tolyl] showed 2.8 log fold reduction in bacterial count of dormant forms of mycobacterium which was more potent than first line drugs isoniazid, ciprofloxacin, rifampicin and moxifloxacin. Having activities against both active and dormant forms of M. tuberculosis, I [R = p-tolyl] may be a useful candidate for the development of new drugs to treat tuberculosis. The experimental process involved the reaction of 4-(4-Acetylpiperazin-1-yl)benzaldehyde(cas: 890092-19-0).Product Details of 890092-19-0

The Article related to benzoimidazolyl phenylpiperazinyl acrylonitrile preparation antimycobacterial activity sar lipophilicity, propanenitrile benzoimidazolyl phenylpiperazinyl preparation antimycobacterial activity sar lipophilicity, acrylonitrile, antimycobacterial activity, benzimidazole, nutrient starvation test, propanenitrile and other aspects.Product Details of 890092-19-0

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On September 23, 2010, Hansen, C. Henrik published a patent.Computed Properties of 890092-19-0 The title of the patent was Preparation of substituted 2-phenyl-3H-quinazolin-4-ones and analogs as antiinflammatory and cardiovascular agents. And the patent contained the following:

The invention is related to the preparation of 2-phenyl-3H-quinazolin-4-ones and analogs, e.g, 2-[4-(4-hydroxypiperidin-1-yl)phenyl]-5,7-dimethoxypyrido[2,3-d]pyrimidin-4(3H)-one (I), that are useful in regulating the expression of interleukin-6 (IL-6) and/or vascular cell adhesion mol.-1 (VCAM-1), and their use in the treatment and/or prevention of cardiovascular and inflammatory diseases and related disease states, such as atherosclerosis, asthma, arthritis, cancer, multiple sclerosis, psoriasis, and inflammatory bowel diseases, and autoimmune disease(s). Thus, cyclization of 2-amino-4,6-dimethoxynicotinamide with 4-(4-hydroxypiperidin-1-yl)benzaldehyde gave pyridopyrimidinone I which caused a ≥ 20% inhibition in IL-6 mRNA and in VCAM-1 mRNA at a concentration ≤ 10 μM. Pharmaceutical compositions containing title compounds are also disclosed. The experimental process involved the reaction of 4-(4-Acetylpiperazin-1-yl)benzaldehyde(cas: 890092-19-0).Computed Properties of 890092-19-0

The Article related to phenylquinazolinone preparation interleukin 6 proliferation inhibitor antiinflammatory cardiovascular, vascular cell adhesion mol 1 inhibitor phenylquinazolinone pyridopyrimidinone preparation and other aspects.Computed Properties of 890092-19-0

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On February 15, 2020, Sirim, Mustafa Mert; Krishna, Vagolu Siva; Sriram, Dharmarajan; Unsal Tan, Oya published an article.Product Details of 890092-19-0 The title of the article was Novel benzimidazole-acrylonitrile hybrids and their derivatives: Design, synthesis and antimycobacterial activity. And the article contained the following:

The synthesis and evaluation of some benzimidazole-acrylonitrile hybrid derivatives I [R = Me, cyclohexyl, benzyl, etc.] was described for their in-vitro antimycobacterial activities against Mycobacterium tuberculosis H37Rv. Among the derivatives studied, I [R = p-tolyl] was found to be the most active compound with MIC of 0.78μg/mL against M. tuberculosis. This was a quite good activity compared with ethambutol (MIC = 1.56μg/mL). Moreover, I [R = p-tolyl] showed 2.8 log fold reduction in bacterial count of dormant forms of mycobacterium which was more potent than first line drugs isoniazid, ciprofloxacin, rifampicin and moxifloxacin. Having activities against both active and dormant forms of M. tuberculosis, I [R = p-tolyl] may be a useful candidate for the development of new drugs to treat tuberculosis. The experimental process involved the reaction of 4-(4-Acetylpiperazin-1-yl)benzaldehyde(cas: 890092-19-0).Product Details of 890092-19-0

The Article related to benzoimidazolyl phenylpiperazinyl acrylonitrile preparation antimycobacterial activity sar lipophilicity, propanenitrile benzoimidazolyl phenylpiperazinyl preparation antimycobacterial activity sar lipophilicity, acrylonitrile, antimycobacterial activity, benzimidazole, nutrient starvation test, propanenitrile and other aspects.Product Details of 890092-19-0

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics